臨床研究等提出・公開システム

The Influence of Oral Semaglutide for Vascular Inflammation in Japanese Patients with Type 2 Diabetes -INNOVATION Study (INNOVATION Study)

The Influence of Oral Semaglutide for Vascular Inflammation in Japanese Patients with Type 2 Diabetes (INNOVATION Study)

Tahara Nobuhiro

Kurume University Hospital

Asahi-machi 67, kurume, Fukuoka, JAPAN

ntahara@kurume-u.ac.jp

Kaneko Fumi

Kurume University Hospital

Asahi-machi 67, kurume, Fukuoka, JAPAN

+81-942-65-3749

kaneko_fumi@kurume-u.ac.jp

Recruiting

July. 25, 2022

Interventional

randomized controlled trial

open(masking not used)

active control

parallel assignment

treatment purpose

1) Patients with type 2 diabetes and a glycated hemoglobin level of 7% or more
2) Age of 18 to 90 years at screening and written informed consent to participate in this study
3) Age of less than 60 years with established cardiovascular disease, or age of 60 years or more with at least one cardiovascular risk factor
4) Oral hypoglycemic agents, lipid lowering agents, antihypertensive agents, and antiplatelet agents and doses of them unchanged within 90 days prior to screening
5) No treatment with any incretin-based antidiabetic agents (DPP-4 inhibitors or GLP-1 receptor agonists) within 90 days prior to screening

1. Patients with diabetic ketoacidosis or hyperglycemic hyperosmolar state
2. Patients with severe infection or surgical emergency
3. Patients with a history of hypersensitivity to study drugs
4. Pregnant patients
5. Patients with significant hepatic disorders or liver cirrhosis
6. Patients with a history of stomach resection
7. Patients with a fasting plasma glucose level of 200 mg/dL or more
8. Patients treated with insulin therapy
9. Patients with malignant neoplasms
10. Patients with active inflammatory diseases
11. Patients judged to be inappropriate to participate in this study by investigators
12. Patients treated with a DPP-4 inhibitor or a GLP-1 receptor agonist within 90 days before screening

Both

Patients with type 2 diabetes and a glycated hemoglobin level of 7% or more

Eligible patients were randomly assigned in a 1:1 ratio to receive once-daily oral semaglutide or oral hypoglycemic agents other than semaglutide.

The patients in the semaglutide group were initially treated with 3 mg/day of semaglutide orally for the first 4 weeks. Then the dose was increased to 7 mg/day for the next 4 weeks, and maximally maintained at 14 mg/day thereafter, if needed.

type 2 diabetes

assignment

Changes from baseline after 6 months of treatment in vascular inflammation measured by blood-normalized standardized uptake value, known as a target-to-background ratio by FDG-PET/CT

1. Changes from baseline in FDG activity witin the myocardium, liver, spleen, brain, and fat as measured by FDG-PET/CT
2. Changes from baseline in subcutaneous and visceral fat volume as measured by CT
3. Changes from baseline in daily energy intake and the intake of different nutritional components
4. Changes from baseline in weight, waist circumference, resting blood pressure, and resting heart rate
5. Changes from baseline in serum and urinary diabetic markers including fasting blood glucose, fasting insulin, glycated hemoglobin, urinary glucose excretion, urinary protein excretion, and urinary L-FABP
6. Changes from baseline in lipid profiles (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides)
7. Changes from baseline in serum biomarkers of inflammation and atherosclerosis (high-sensitivity C-reactive protein, asymmetric dimethylarginine, adiponectin, advanced glycation end-products, receptor for advanced glycation end-products, pigment epithelium-derived factor, leptin, ghrelin)
8. Changes from baseline in cardio-ankle vascular index and brachial artery flow-mediated dilation
9. Changes from baseline in accumulated advanced glycation end-products in skin collagen measured with skin autofluorescence by AGE READER

+81-952-34-3357

June. 20, 2022

No

none